18 December 2014

Xigduo XR for the treatment of type II diabetes



US-FDA has approved Xigduo XR, a combination of dapagliflozin + metformin hydrochloride for the treatment of glycemic control in adults with type II diabetes in on October 2014.This unique drug combines two anti-hyperglycemic agents. Dapagliflozin is medicine which acts as an inhibitor of sodium-glucose co-transporter 2 (SGLT2) on the other hand, metformin hydrochloride (HCl) is an extended-release biguanide drug molecule. The drug has been manufactured by Astra-Zeneca.
Type II diabetes is a metabolic disorder characterized by hyperglycemia (high blood sugar) in which the body become insulin resistance and as result sugar level in blood increases significantly leading to hyperglycemia.  Metformin has been used for type II diabetes treatment for long time.
The drug Xigduo XR is available for oral administration. The starting dose for a particular patient has to determined depending on each patient’s current diabetes status and treatment regimen. it is available for oral administration as tablets containing the equivalent of 5 mg dapagliflozin and 500 mg metformin hydrochloride (XIGDUO XR 5 mg/500 mg), 5 mg dapagliflozin and 1000 mg metformin hydrochloride (XIGDUO XR 5 mg/1000 mg), t10 mg dapagliflozin and 500 mg metformin hydrochloride (XIGDUO XR 10 mg/500 mg), or 10 mg dapagliflozin and 1000 mg metformin hydrochloride (XIGDUO XR 10 mg/1000 mg). The maximum daily recommended dose is for dapagliflozin would be 10 mg and for metformin HCl would be 2,000 mg.  The recommended use has been prescribed as once daily in the morning with food, to reduce the gastrointestinal side effects caused by metformin. 
 
Clinnovo is a clinical innovation company. It is pioneer CRO industry in India. Clinnovo offers professional Clinical Research Course,  Clinical Data Management Course, SAS Courses and Imaging Training. Clinnovo has been serving different bio-pharma industries across the world with excellence and high quality.
For more information on Courses and Training contact at: +91 9912868928, 040 64635501.

No comments:

Post a Comment